DNA Methylation as a Biomarker for Cardiovascular Disease Risk

Myungjin Kim, Tiffany I. Long, Kazuko Arakawa et al. · 2010

Read DNA Methylation as a Biomarker for Cardiovascular Disease Risk by Myungjin Kim, Tiffany I. Long, Kazuko Arakawa et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009692.txt.

Description

Doctors judge heart disease risk from blood pressure, cholesterol, and family history. Myungjin Kim and colleagues tested a molecular option in PLOS ONE in 2010. They asked whether DNA methylation could flag higher risk. Methylation is a chemical mark that can silence genes.

Methylation patterns differ between people and can shift with age and habits. The study weighed whether those patterns track with known risk for cardiovascular disease. A blood-based mark that flags risk early could guide prevention before symptoms appear. The authors present the approach as a candidate tool that needs wider testing.

Catalog record

CREATORMyungjin Kim, Tiffany I. Long, Kazuko Arakawa et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009692

Browse the full library · About the Tower of Babel